Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression, Insights from UC San Diego Health - Episode 6

Exploring the First FDA-Approved Treatment to Delay T1D Onset: Mechanism of Action and Treatment Impact

June 11, 2024

Jennifer D. Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP, Steven Edelman, MD, Andrea Stallings, PA, Schafer Boeder, MD

Diabetes specialists from UCSD discuss teplizumab, the first FDA-approved drug for delaying onset of T1D, highlighting its benefits and mechanism of action.

EP. 1: Insights into the Burden of T1D: Genetic Links and Familial Considerations from UCSD Practitioners

EP. 2: The Vital Importance of Understanding and Addressing Training Gaps in Endocrinology Surrounding T1D Stages

EP. 3: The Crucial Impact of Early Intervention in Preventing T1D Stage Progression

EP. 4: Navigating T1D Risk Screening: Identifying Ideal Candidates, Understanding Autoantibodies, and Determining Timing for Rescreening

EP. 5: Understanding Autoantibody Screening Tests: Methods, Interpretation, and Analysis Practicalities

Now Viewing

EP. 6: Exploring the First FDA-Approved Treatment to Delay T1D Onset: Mechanism of Action and Treatment Impact

EP. 7: Exploring the TN-10 Teplizumab Clinical Trial: Patient Demographics and Efficacy Insights

EP. 8: Teplizumab Infusion Protocol: Clinical Processes and Strategies for Infusion Access Enhancement

EP. 9: Key Insights and Practical Tips: Wisdom from UCSD Practitioners for Effective T1D Management